Form 4: Korro Bio Director Boosts Stake with $5.0M Investment

Mohamad Makhzoumi, a Director and 10% owner of Korro Bio, Inc., indirectly acquired common stock and pre-funded warrants totaling approximately $5.0 million from the issuer.

Summary

• Mohamad Makhzoumi, a Director and 10% owner of Korro Bio, Inc. (KRRO), indirectly acquired additional securities.
• The acquisition occurred on March 10, 2026, from the Issuer, pursuant to a Subscription Agreement dated March 9, 2026.
• NEA 17, an entity where Mr. Makhzoumi is a manager, acquired 207,100 shares of common stock at a price of $11.11 per share.
• NEA 17 also acquired 242,945 pre-funded warrants, exercisable at $0.001 per share, with an effective purchase price of $11.109 per warrant.
• The pre-funded warrants are immediately exercisable, subject to an ownership cap of 9.99% (which can be increased to 19.99% with 61 days' notice).
• Following these transactions, NEA 17 indirectly beneficially owns 1,297,893 shares of common stock and 242,945 pre-funded warrants.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a significant investment by a Director and 10% owner typically reflects high confidence in the company's valuation and future growth potential.

Positives

• A Director and 10% owner, Mohamad Makhzoumi, through NEA 17, increased their stake in Korro Bio, Inc., signaling confidence in the company's future prospects.
• The acquisition of common stock and pre-funded warrants represents a significant investment of approximately $5.0 million into the company.
• The pre-funded warrants offer flexibility for future conversion into common stock at a nominal exercise price.

Risks

• The exercise of pre-funded warrants is subject to an ownership cap, initially 9.99%, which could limit immediate full conversion if not adjusted.
• The value of the acquired common stock and warrants is subject to market fluctuations and the company's performance.

Future Outlook

The acquisition of pre-funded warrants, exercisable at any time, provides NEA 17 with the option to increase its direct common stock ownership in Korro Bio, Inc. in the future, subject to ownership limitations.

Industry Context

StockSavvy.ai notes that significant insider buying, especially from a 10% owner and Director, can often be interpreted by the market as a strong vote of confidence in a company's future prospects, particularly in the biotechnology sector where R&D milestones and clinical trial results heavily influence valuations. This investment by NEA 17, a prominent venture capital firm, suggests a positive long-term view on Korro Bio's strategic direction and potential.

Related Party Transactions

• The acquisition of common stock and pre-funded warrants by NEA 17, an entity associated with Mohamad Makhzoumi, a Director and 10% owner of Korro Bio, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this significant insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The capital raised through this issuance provides additional funding for the company's operations and strategic initiatives.

Next Steps

• NEA 17 may exercise its pre-funded warrants at any time to acquire additional common stock, subject to the specified ownership limitations.

Key Dates

Recommendation

The substantial investment by a Director and 10% owner, Mohamad Makhzoumi, through NEA 17, signals strong conviction in Korro Bio's future. This insider buying, especially from a sophisticated institutional investor like NEA, often precedes positive developments or reflects an undervalued stock, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

Korro Bio, KRRO, Mohamad Makhzoumi, NEA 17, Insider Buying, Form 4, Common Stock, Pre-Funded Warrants, Equity Investment, Biotechnology, SEC Filing, Subscription Agreement, Director, 10% Owner